泰素加卡铂治疗中晚期非小细胞肺癌的临床疗效  

The efficacy of treating intermediate and late non-small cell lung cancer with taxol plus carboplatin

作　　者：张立新[1] 陈晓红[2] 

机构地区：[1]上海市浦东新区人民医院血液科,上海201200 [2]上海市第二人民医院呼吸科,上海200011

出　　处：《上海医药》2002年第1期22-24,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:探讨泰素加卡铂联合化疗方案对非小细胞肺癌的疗效.方法:24例中晚期非小细胞肺癌应用泰素1 35mg/m2加卡铂300mg/m2联合化疗,间隔28天,重复2～3次.结果:19例初治者和5例复治者近期有效率分别为68.4%和40.0%,总有效率为62.5%,中位生存时间为9.2月.主要不良反应为骨髓抑制、关节或肌肉疼痛.结论:泰素加卡铂联合化疗方案对中晚期非小细胞肺癌有较好疗效,不良反应小.Objective:To investigate the efficacy of treating taxol plus carboplatin in the treatment of non-small cell lung cancer. Methods:Twenty-four patients with intermediate and late non-small cell lung cancer were treated with combined taxol 135mg/m~ 2 and carboplatin 300mg/m~ 2 for 2-3 courses with time intervals of 28 days. Results:The response rates in 19 initial treatment cases and 5 cases treated in time of relapse were 68.4% and 40.0% respectively. The global response rate was 62.5%. The mediam survival time was 9.2 months. The main side effects were arrest of bone marrow, arthralgia and mascular pain.Conclusion:The efficacy of treating intermediate and late non-small cell lung cancer with combined taxol and carboplatin chemotherapy is fairly good. The adverse reactions are mild and tolerable.

关 键 词：泰素 卡铂 治疗 中晚期非小细胞肺癌 临床疗效 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]